Literature DB >> 7517722

Antibodies to myeloid precursor cells in autoimmune neutropenia.

K R Hartman1, V F LaRussa, S W Rothwell, T O Atolagbe, F T Ward, G Klipple.   

Abstract

Antibodies to mature blood neutrophils and to bone marrow myeloid cells have been described in the sera of some patients with apparent autoimmune neutropenia. To further explore the prevalence and specificities of antibodies to myeloid precursor cells, we evaluated sera from 148 patients with suspected autoimmune neutropenia for the presence of antibodies to neutrophils, to cultured myeloid cell lines, and to highly purified bone marrow myeloid progenitor cells. Using an immunofluorescence flow cytometric assay, we identified IgG antibodies in 42 (28%) of these sera that bound specifically to K562 cells, a multilineage cell line originally derived from a patient with chronic myelogenous leukemia. Twenty-two (15%) of the sera also contained IgG antibodies that bound specifically to the primitive myelomonocytic leukemia cell line KG1a. Twenty-five (17%) of the sera had IgG antibodies to myeloid cell lines in the absence of antibodies to mature neutrophils. There was a trend toward more severe neutropenia in patients with antibodies to K562 cells, without antineutrophil antibodies. In further studies, antibodies from 12 sera bound to mononuclear CD34+ cells that had been purified from normal human bone marrow by an immunomagnetic separation procedure. Moreover, two of these sera suppressed the growth of granulocyte-macrophage colony-forming units (CFU-GM) in methylcellulose cultures. The presence of antibodies to primitive hematopoietic cells in the sera of some patients with suspected immune neutropenia suggests that these antibodies may have a role in the pathogenesis of the neutropenia observed.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7517722

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  9 in total

Review 1.  Neutrophils in the pathogenesis and manifestations of SLE.

Authors:  Mariana J Kaplan
Journal:  Nat Rev Rheumatol       Date:  2011-09-27       Impact factor: 20.543

Review 2.  Diagnosis and management of primary autoimmune neutropenia in children: insights for clinicians.

Authors:  Piero Farruggia; Carlo Dufour
Journal:  Ther Adv Hematol       Date:  2015-02

Review 3.  Anaemia in systemic lupus erythematosus: from pathophysiology to clinical assessment.

Authors:  S Giannouli; M Voulgarelis; P D Ziakas; A G Tzioufas
Journal:  Ann Rheum Dis       Date:  2005-08-03       Impact factor: 19.103

4.  Clonal predominance of CD8(+) T cells in patients with unexplained neutropenia.

Authors:  Marcin Wojciech Wlodarski; Zachary Nearman; Ying Jiang; Alan Lichtin; Jaroslaw Pawel Maciejewski
Journal:  Exp Hematol       Date:  2008-03       Impact factor: 3.084

Review 5.  [Autoimmune thrombocytopenia, neutropenia and hemolysis].

Authors:  A Greinacher; J Bux; A Salama
Journal:  Internist (Berl)       Date:  2009-03       Impact factor: 0.743

6.  Suppression of haematopoiesis by IgG autoantibodies from patients with systemic lupus erythematosus (SLE).

Authors:  H Liu; K Ozaki; Y Matsuzaki; M Abe; M Kosaka; S Saito
Journal:  Clin Exp Immunol       Date:  1995-06       Impact factor: 4.330

Review 7.  Immune neutropenias of infancy and childhood.

Authors:  Piero Farruggia
Journal:  World J Pediatr       Date:  2015-11-19       Impact factor: 2.764

8.  Reduction of CFU-GM and circulating hematopoietic progenitors in a subgroup of children with chronic neutropenia associated with severe infections and delayed recovery.

Authors:  Fabio Timeus; Nicoletta Crescenzio; Luiselda Foglia; Alessandra Doria; Maria Giuseppina Stillitano; Emanuela Garelli; Raffaela Mazzone; Laura Vivalda; Stefano Vallero; Ugo Ramenghi; Paola Saracco
Journal:  PLoS One       Date:  2019-03-14       Impact factor: 3.240

9.  Immune-mediated neutropenia in 2 dogs.

Authors:  P M McManus; C Litwin; L Barber
Journal:  J Vet Intern Med       Date:  1999 Jul-Aug       Impact factor: 3.333

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.